Literature DB >> 26230317

Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.

Megha Verma, David Beaulieu-Abdelahad, Ghania Ait-Ghezala, Rena Li, Fiona Crawford, Michael Mullan, Daniel Paris.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0128224.].

Entities:  

Year:  2015        PMID： 26230317      PMCID： PMC4521847          DOI： 10.1371/journal.pone.0134776

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


The following information is missing from the Funding section: This study was also funded by the Roskamp Foundation.
  1 in total

1.  Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD.

Authors:  Megha Verma; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Rena Li; Fiona Crawford; Michael Mullan; Daniel Paris
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240
  1 in total
  1 in total

1.  A 3-month-delayed treatment with anatabine improves chronic outcomes in two different models of repetitive mild traumatic brain injury in hTau mice.

Authors:  Alexander Morin; Benoit Mouzon; Scott Ferguson; Daniel Paris; Nicole Saltiel; Mackenzie Browning; Mike Mullan; Fiona Crawford
Journal:  Sci Rep       Date:  2021-04-12       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.